Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034075 | 1.00 | GRM4 (0.43) | GRM4POLBHRH4EPHX1ROCK1 | |
| SCHEMBL2035178 | 0.83 | HRH4 (0.43) | POLBHRH4ROCK1CDK2CDC7 | |
| SCHEMBL2035177 | 0.83 | HRH4 (0.43) | POLBHRH4ROCK1CDK2CDC7 | |
| SCHEMBL2036751 | 0.73 | POLB (0.70) | GRM4POLBHRH4ROCK1CDK2 | |
| SCHEMBL2036753 | 0.73 | POLB (0.70) | GRM4POLBHRH4ROCK1CDK2 | |
| SCHEMBL2037477 | 0.73 | POLB (0.70) | GRM4POLBHRH4ROCK1CDK2 | |
| SCHEMBL2051615 | 0.69 | POLB (0.47) | POLBROCK1CDC7RAB9A | |
| SCHEMBL2051616 | 0.69 | POLB (0.47) | POLBROCK1CDC7RAB9A | |
| SCHEMBL2033840 | 0.69 | POLB (0.41) | POLBHRH4CDK2CDC7 | |
| SCHEMBL2669681 | 0.69 | EPHX1 (0.47) | EPHX1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516397-B1 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME (NL) | 2016-07-13 | — | — | EP | disclosed |
| US-8952001-B2 | Amino-heteroaryl derivatives as HCN blockers | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| CN-102884048-B | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2014-07-23 | — | — | CN | disclosed |
| CN-102884048-A | Amino-heteroaryl derivatives as HCN blockers | MSD OSS BV | 2013-01-16 | — | — | CN | disclosed |
| EP-2516397-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | MSD Oss B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076723-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | N.V. ORGANON (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264728-A1 | AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS | HCN1, HCN3, HCN2 | GRM4 1061/4885POLB 3931/4885HRH4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.